查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1771539

全球癌症伴随诊断市场：市场规模、份额、趋势分析（按产品/服务、技术、疾病类型、最终用途和地区）、细分市场预测（2025-2030 年）

Oncology Companion Diagnostic Market Size, Share & Trends Analysis Report By Product & Service, By Technology (PCR, IHC, NGS), By Disease Type (Breast Cancer), By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

癌症伴随诊断市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球癌症伴随诊断市场规模预计到2030年将达到83.8亿美元，2025年至2030年期间的复合年增长率为9.02%。

由于伴随诊断能够提供更多关键基因组信息，从而帮助患者做出明智的决策并为患者设计标靶治疗方法，因此对全面基因组检测和癌症伴随诊断的需求正在增加。

Gleevec/Glivec（Imatinib）和Herceptin（曲妥珠单抗）等需要在处方前进行伴随诊断 (CDx) 检测的药物的上市，增加了癌症伴随诊断的收益。由于临床试验中有大量与伴随诊断相关的癌症药物，预计未来将持续下去。除了作为治疗的专属或综合检测外，伴随诊断还在临床试验参与者的选择中发挥关键作用，因为如果患者俱有生物标记靶点，候选药物更有可能表现出更高的反应率。

与CDx应用相关的经济奖励正在鼓励药物开发人员将药物与诊断测试配对。然而，诊断公司面临着来自支付方/医疗保健提供者和药品製造商的相互衝突的需求。此外，监管机构对协调诊断和药物开发时间表有着严格的政策。因此，预计诊断公司将扩大其CDx开发的范围，而不是专注于将单一诊断与特定药物配对。

癌症伴随诊断市场报告重点

  • 在个人化医疗进步和癌症发病率不断上升的推动下，产品领域预计将在 2024 年占据市场主导地位，份额达到 66.14%，而服务领域预计将在预测期内实现最快的复合年增长率。
  • 预计聚合酵素链锁反应(PCR) 领域将在 2024 年占据市场主导地位，占有 28.03% 的份额，而次世代定序(NGS) 领域预计将在预测期内实现最快的复合年增长率。
  • 预计非小细胞肺癌领域将在 2024 年占据市场主导地位，占有 30.32% 的份额，而乳癌领域预计在预测期内实现最快的复合年增长率，达到 9.65%。
  • 2024年，北美占据了整个神经假体市场的主导地位，市占率超过40.17%。这得归功于北美地区神经植入製造商的庞大规模、高额的研发投入以及来自政府和私人机构的资金支持。例如，美国国防高级研究计划局 (DARPA) 和美国国家神经疾病和中风研究所 (NIH) 与联邦机构合作，为神经植入的进一步研发提供资金倡议。
  • 由于跨国医疗保健公司进入亚太地区推广安全有效的医疗程序以及消费者意识层级的提高，亚太地区预计将成为成长最快的地区。
  • 预计在预测期内，策略联盟和併购将使产业竞争水准保持在高水准。

目录

第一章 分析方法与范围

第二章执行摘要

第三章癌症伴随诊断市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
    • 市场机会
    • 市场挑战
  • 癌症伴随诊断市场：分析工具
  • 商业环境分析
    • 产业分析：波特五力分析
    • PESTEL分析

第四章癌症伴随诊断市场：按产品和服务的估计和趋势分析

  • 按产品/服务分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 癌症伴随诊断市场：产品与服务展望
  • 市场规模预测及趋势分析（2018-2030年）
  • 产品
    • 装置
    • 耗材
    • 软体
  • 服务

第五章癌症伴随诊断市场：按技术分類的估计和趋势分析

  • 按技术分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 癌症伴随诊断市场：技术展望
  • 市场规模预测及趋势分析（2018-2030年）
  • 聚合酵素链锁反应（PCR）
  • 次世代定序（NGS）
  • 免疫组织化学（IHC）
  • 原位杂合反应（ISH）/萤光原位杂合反应（FISH）
  • 其他技术

第六章癌症伴随诊断市场：依疾病类型估计与趋势分析

  • 按疾病类型分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 癌症伴随诊断市场：依疾病类型展望
  • 市场规模预测及趋势分析（2018-2030年）
  • 乳癌
  • 非小细胞肺癌
  • 大肠直肠癌
  • 白血病
  • 黑色素瘤
  • 摄护腺癌
  • 其他的

第七章癌症伴随诊断市场：依最终用途的估计和趋势分析

  • 按最终用途分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 癌症伴随诊断市场：按最终用途分類的展望
  • 市场规模预测及趋势分析（2018-2030年）
  • 医院
  • 病理学/诊断实验室
  • 学术医疗中心

第八章癌症伴随诊断市场：按地区估计和趋势分析

  • 各地区市场占有率分析（2024 年及 2030 年）
  • 区域仪表板
  • 全球市场概况：按地区
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 北美：SWOT分析
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲：SWOT分析
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区：SWOT分析
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲：SWOT分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 主要企业近期趋势及影响分析
  • 公司分类
  • 公司热图分析
  • 公司简介
    • Agilent Technologies, Inc.
    • Illumina, Inc.
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • Foundation Medicine, Inc.
    • Myriad Genetics, Inc.
    • F. Hoffmann-La Roche Ltd
    • BIOMERIEUX
    • Abbott
    • Leica Biosystems Nussloch GmbH
    • Guardant Health
    • EntroGen, Inc.
Product Code: GVR-4-68039-049-7

Oncology Companion Diagnostic Market Growth & Trends:

The global oncology companion diagnostic market size is expected to reach USD 8.38 billion by 2030, expanding at a CAGR of 9.02% from 2025 to 2030, according to a new report by Grand View Research, Inc. Expanding access to important genomic information with the aid of companion diagnostics enables informed decision making for designing the targeted treatment approaches for their patients, thereby increasing demand for comprehensive genomic testing and oncology companion diagnostics.

The commercial launch of drugs including Gleevec (imatinib) and Herceptin (trastuzumab) that require Companion Diagnostics (CDx) testing before prescription has increased revenue generation in the oncology companion diagnostics field. This growth is expected to continue in the future owing to a substantial number of CDx associated oncology drugs in clinical trials. Apart from functioning as exclusive or inclusive tests for therapies, CDx also plays a crucial role during participant selection in clinical trials. This is because there is an increased potential for a novel drug candidate to show a better response rate if the patient has its biomarker target.

The economic incentives associated with the use of CDx have encouraged drug developers to combine their drugs with diagnostic tests. However, the diagnostic manufacturers face conflicting demands from payers/providers on one hand and drug manufacturers on the other hand. The regulatory bodies also have stringent policies to align the development timelines of diagnostics and drugs. Therefore, the diagnostic companies are expected to broaden their scope of CDx development instead of focusing on the attainment of a match between a single diagnostic with a specific drug.

Oncology Companion Diagnostic Market Report Highlights:

  • The products segment dominated the market with a share of 66.14% in 2024, driven by advancements in personalized medicine and the increasing prevalence of cancer and the services segment is expected to register the fastest CAGR during the forecast period
  • The Polymerase Chain Reaction (PCR) segment dominated the market with a share of 28.03% in 2024 and the next-generation Sequencing (NGS) segment is expected to register the fastest CAGR during the forecast period
  • The non-small cell lung cancer segment dominated the market, with a share of 30.32% in 2024 and the breast cancer segment is expected to register the fastest CAGR of 9.65% during the forecast period
  • In 2024, North America dominated the overall neuroprosthetics market at over 40.17% owing to the large presence of neural implants manufacturers, higher R&D investments, and the availability of funds from both government and private institutes. For instance, the Defense Advanced Research Project Agency (DARPA) and National Institute of Neurological Disorders and Stroke (NIH)in collaboration with the federal agencies are instrumental in providing funds to support R&D initiatives for the further development of neural implants.
  • Asia Pacific is anticipated to be the fastest growing segment due to the introduction of multinational healthcare establishments promoting safe and effective medical procedures along with the rising awareness levels amongst consumers.
  • Strategic collaborations and mergers & acquisitions are expected to keep the industry rivalry level high over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Oncology Companion Diagnostic Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Oncology Companion Diagnostic Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Oncology Companion Diagnostic Market: Product & Services Estimates & Trend Analysis

  • 4.1. Product and Services Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Oncology Companion Diagnostic Market by Product & Services Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Product
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Instrument
      • 4.5.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Consumables
      • 4.5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Software
      • 4.5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Services
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Oncology Companion Diagnostic Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Oncology Companion Diagnostic Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Polymerase Chain Reaction (PCR)
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Next-generation Sequencing (NGS)
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Immunohistochemistry (IHC)
    • 5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
    • 5.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Other Technologies
    • 5.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Oncology Companion Diagnostic Market: Disease Type Estimates & Trend Analysis

  • 6.1. Disease Type Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Oncology Companion Diagnostic Market by Disease Type Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Breast Cancer
    • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Non-small Cell Lung Cancer
    • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Colorectal Cancer
    • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Leukemia
    • 6.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Melanoma
    • 6.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.10. Prostate Cancer
    • 6.10.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.11. Others
    • 6.11.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Oncology Companion Diagnostic Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Oncology Companion Diagnostic Market by Disease Type Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Hospital
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Pathology/Diagnostic Laboratory
    • 7.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Academic Medical Center
    • 7.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Oncology Companion Diagnostic Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. North America: SWOT Analysis
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe: SWOT Analysis
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific: SWOT Analysis
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America: SWOT Analysis
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA: SWOT Analysis
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Agilent Technologies, Inc.
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Illumina, Inc.
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. QIAGEN
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Thermo Fisher Scientific Inc.
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. Foundation Medicine, Inc.
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Myriad Genetics, Inc.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. F. Hoffmann-La Roche Ltd
      • 9.4.7.1. Financial Performance
      • 9.4.7.2. Product Benchmarking
      • 9.4.7.3. Recent Developments/ Strategic Initiatives
    • 9.4.8. BIOMERIEUX
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Abbott
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Leica Biosystems Nussloch GmbH
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives
    • 9.4.11. Guardant Health
      • 9.4.11.1. Participant's Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Product Benchmarking
      • 9.4.11.4. Recent Developments/ Strategic Initiatives
    • 9.4.12. EntroGen, Inc.
      • 9.4.12.1. Participant's Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Product Benchmarking
      • 9.4.12.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 4 North America oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 5 North America oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 6 North America oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S. oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 8 U.S. oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 10 U.S. oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 12 Canada oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 13 Canada oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 14 Canada oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 16 Mexico oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 17 Mexico oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 18 Mexico oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 21 Europe oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 22 Europe oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 23 Europe oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 25 Germany oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 26 Germany oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 27 Germany oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 29 UK oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 30 UK oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 31 UK oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 33 France oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 34 France oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 35 France oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 37 Italy oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 38 Italy oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 39 Italy oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 41 Spain oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 42 Spain oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 43 Spain oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Denmark oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 45 Denmark oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 46 Denmark oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 47 Denmark oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Sweden oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 49 Sweden oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 50 Sweden oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 51 Sweden oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Norway oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 53 Norway oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 54 Norway oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 55 Norway oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 61 China oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 62 China oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 63 China oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 64 China oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 66 Japan oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 67 Japan oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 68 Japan oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 70 India oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 71 India oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 72 India oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 73 South Korea oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 74 South Korea oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 75 South Korea oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 76 South Korea oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Australia oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 78 Australia oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 79 Australia oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 80 Australia oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Thailand oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 82 Thailand oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 83 Thailand oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 84 Thailand oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 86 Latin America oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 87 Latin America oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 88 Latin America oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 89 Brazil oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 90 Brazil oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 91 Brazil oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 92 Brazil oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 93 Argentina oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 94 Argentina oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 95 Argentina oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 96 Argentina oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 97 MEA oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 98 MEA oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 99 MEA oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 100 MEA oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 101 MEA oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 102 South Africa oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 103 South Africa oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 104 South Africa oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 105 South Africa oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 110 UAE oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 111 UAE oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 112 UAE oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 113 UAE oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 114 Kuwait oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
  • Table 115 Kuwait oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
  • Table 116 Kuwait oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
  • Table 117 Kuwait oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Oncology companion diagnostic market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Oncology companion diagnostic market: Product & Services outlook key takeaways
  • Fig. 20 Oncology companion diagnostic market: Product & Services movement analysis
  • Fig. 21 Passive immunization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Preventive vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Oncology companion diagnostic market: Technology outlook key takeaways
  • Fig. 24 Oncology companion diagnostic market: Technology movement analysis
  • Fig. 25 Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Next-generation Sequencing (NGS) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 mRNA-based vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Other Technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Oncology companion diagnostic market: Disease Type outlook key takeaways
  • Fig. 30 Oncology companion diagnostic market: Disease Type movement analysis
  • Fig. 31 Breast Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Non-small Cell Lung Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Colorectal Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Leukemia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Melanoma market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Prostate Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Others estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Oncology companion diagnostic market: End Use outlook key takeaways
  • Fig. 39 Oncology companion diagnostic market: End Use movement analysis
  • Fig. 40 Hospital & retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Government suppliers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Academic Medical Center market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Regional marketplace outlook, 2024 & 2030 (USD million)
  • Fig. 44 Regional marketplace: Key takeaways
  • Fig. 45 North America Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 U.S. Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Canada Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Mexico Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Europe Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 UK Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Germany Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 France Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Spain Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Italy Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Denmark Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Sweden Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Norway Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Asia Pacific Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Japan Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 China Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 India Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Australia Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 South Korea Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Thailand Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Market participant categorization
  • Fig. 84 Oncology companion diagnostic market position analysis, 2024
  • Fig. 85 Strategic framework